Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors in the management of breast cancer: current data and future prospects.

BMC medicine - 13 Aug 2015

Livraghi Luca, Garber Judy E

Abstract excerpt

Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms
Share to DNA Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 26268938
DOI: 10.1186/s12916-015-0425-1
PMCID: PMC4535298

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors in the management of breast cancer: current data and future prospects.PMID 26268938Read ↗

Advances in PARP inhibitors for the treatment of breast cancer.Semantic proximity Read ↗

PARP inhibitors in breast cancer: BRCA and beyond.Semantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

Therapeutic advances and application of PARP inhibitors in breast cancerSemantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

PARP inhibitors and their evolving role in breast cancer.Semantic proximity Read ↗

An Overview of PARP Inhibitors for the Treatment of Breast CancerSemantic proximity Read ↗

PARP inhibition in breast cancer.Semantic proximity Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.Semantic proximity Read ↗

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read ↗

Advances in using PARP inhibitors to treat cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.